Company Overview and News

 
CORI / Corium International, Inc. / PERCEPTIVE ADVISORS LLC - AMENDMENT NO. 3 TO SCHEDULE 13G (Passive Investment)

2018-10-16 sec.gov
Amendment No. 3 to Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHI
CORI

 
CORI / Corium International, Inc. / PERCEPTIVE ADVISORS LLC - AMENDMENT NO. 3 TO SCHEDULE 13G (Passive Investment)

2018-10-16 sec.gov
Amendment No. 3 to Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHI
CORI

 
CORI / Corium International, Inc. / Broadfin Capital, LLC - null (Passive Investment)

2018-10-15 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G
CORI

 
CORI / Corium International, Inc. / Broadfin Capital, LLC - null (Passive Investment)

2018-10-15 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G
CORI

2
Corium's (CORI) Shares Surge on Merger Agreement With Gurnet

2018-10-15 zacks
Corium International, Inc. (CORI - Free Report) announced that it has entered a definitive merger agreement with a private investment firm, Gurnet Point Capital. Per this agreement, Gurnet will acquire Corium and will also take the company private.
CORI AGN BIIB

1
Why Corium Shares Are Booming

2018-10-12 247wallst - 1
Corium International Inc. (NASDAQ: CORI) shares jumped on Friday after the company announced that it entered into a definitive merger agreement under which Gurnet Point Capital (GPC) will acquire Corium. Corium’s board of directors has unanimously approved the transaction.
CORI

 
Corium's stock rockets to pace premarket gainers after Gurnet buyout deal

2018-10-12 marketwatch
Share of Corium International Inc. CORI, -0.24% rocketed 50.7% to pace all premarket gainers Friday, after the biotechnology company agreed to be acquired by private investment firm Gurnet Point Capital. Under terms of the deal, announced late Thursday, Gurnet will pay $12.50 in cash for each Corium share outstanding, a 50.4% premium to Thursday's closing price of $8.31. The deal is expected to close by the end of the year.
CORI

1
CORI / Corium International, Inc. SC14D9C

2018-10-11 sec.gov - 1
UNITED STATES
CORI

1
Corium Announces Agreement for Gurnet Point Capital to Purchase All Outstanding Shares

2018-10-11 globenewswire - 1
Gurnet Point Capital to Expand Operations While Focusing on the Approval and Commercialization of Corium’s Corplex Donepezil
CORI MAYNF

 
Corium to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference

2018-09-24 globenewswire
MENLO PARK, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that Peter Staple, Corium’s President and Chief Executive Officer, will present at the Cantor Fitzgerald Global Healthcare Conference on Monday, October 1, 2018 at 2:20 PM EDT.
CORI MAYNF

 
Corium to Present at the H. C. Wainwright 20th Annual Global Investment Conference

2018-08-29 globenewswire
MENLO PARK, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that Peter Staple, Corium’s President and Chief Executive Officer, will present at the H.C. Wainwright 20th Annual Global Investment Conference on Wednesday, September 5, 2018 at 9:35 AM EDT.
CORI MAYNF

4
Week 35 Breakout Forecast: Short-Term Picks To Give You An Edge

2018-08-27 seekingalpha - 1
Publishing 2 of the 8 new Week 35 breakout stocks that are available only to subscribers with better than 10% short-term upside potential.
CDMO CORI CMCM

 
CORI / Corium International, Inc. null

2018-08-16 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4*)>+CS],*,2 P(&]B:@H\/"]4>7!E+UA/8FIE8W0O0V]L;W)3 M<&%C92]$979I8V5'
CORI

 
CORI / Corium International, Inc. null

2018-08-16 sec.gov
June 29, 2018
CORI

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to CORI / Corium International, Inc. on message board site Silicon Investor.

Corixa [CRXA] - cancer vaccines Corixa [CRXA] - cancer vaccines Corixa [CRXA] - cancer vaccines CRIO: Corio, Inc. CRIO: Corio, Inc. CRIO: Corio, Inc.
Corinthians - Chapter 13 Corinthians - Chapter 13 Corinthians - Chapter 13 Corillian (CORI) Corillian (CORI) Corillian (CORI)
Corio (CRIO) Corio (CRIO) Corio (CRIO)
CUSIP: 21887L107